Phillips-Medisize Corp. has signed an agreement to supply Sanofi with insulin pen components for its diabetes treatment. Phillips-Medisize has expanded its automated production line at its injection pen component plant in Kontiolahti, Finland, to accommodate Sanofi’s demand.
The new pen is an easy-to-use disposable pen for the administration of lixisenatide and the finished device being produced for the Japanese market. The manufacturing involves injection molding technology, assembly and tray handling robots, various measuring and testing systems, as well as pad printing. Phillips-Medisize installed the automated assembly line, which includes multiple camera inspection points, and implemented the project, including all validations required.
Phillips-Medisize president and chief executive officer Matt Jennings said, "This agreement confirms our in-house tooling and automation expertise, combined with excellent project management capabilities are highly valued by our customers. We will continue to develop our competency to offer them an even quicker service for their drug delivery device projects and are delighted to contribute to the rapid growth of the Sanofi diabetes treatment business."